Michigan Institute of Urology | Strategic Alliance Partners

In this interview, Kenneth M. Kernen, MD, describes his practice’s Jelmyto program and offers advice for urologists interested in implementing it in their practice.

In this video, Ryan J. Nelson, DO, and Steven Ogilvy, PA-C, demonstrate the retroperitoneal single-port robotic surgical technique for a kidney tumor.

MIU seizes innovation opportunities presented by dynamic national urology platform caring for nearly one-half million patients.

In this interview, Jason M. Hafron, MD, discusses the “buzz” surrounding the meeting and touches on clinical topics including germline and somatic testing, PARP inhibitors, and mitomycin-containing reverse thermal gel (Jelmyto).

“[Out] of everything going on, this is probably 1 of the most exciting areas in prostate cancer,” says Jason M. Hafron, MD.

“I think as our understanding of mutations [and] our understanding the PARP inhibitors [grows], if the data pans out, we'll be using these earlier and earlier in patients, which I think we'll [will allow us to] see probably more benefit,” says Jason M. Hafron, MD.

“The future in bladder cancer [and] prostate cancer is really exploding. The therapeutics are coming faster than we ever thought,” says Jason M. Hafron, MD.

“What's great about [Jelmyto] is you can avoid a pretty morbid operation in a typically unhealthy older population, and treat them with localized therapy,” says Jason M. Hafron, MD.

“It's very important that the urologists get involved with germline and somatic testing,” says Jason M. Hafron, MD.

Determining grade of disease is important, as nephron-sparing approaches may be feasible.